PhoenixBio CoTSE:6190 +2.75%57 Interest Coverage is 32.12 as of Mar. 2026, which is 34% below its 10-year median of 48.72. GuruFocus rates TSE:6190 with a GF Score™ of 57/100 and a GF Value™ of 円359.65 (Fairly Valued). The stock has 5 warning signs investors should review. Among 377 Biotechnology companies, PhoenixBio Co ranks worse than 69.5% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. PhoenixBio Co's
Operating Income
for the
six
months ended in Mar. 2026 was 円77 Mil. PhoenixBio Co's Interest Expense for the
six
months ended in Mar. 2026 was 円-2 Mil.
PhoenixBio Co's interest coverage for the quarter that ended in Mar. 2026 was 32.12.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for PhoenixBio Co's Interest Coverage or its related term are showing as below:
TSE:6190'
s Interest Coverage Range Over the Past 10 Years
Min: 3.78 Med: 48.72 Max: 165.51
Current: 17.25
TSE:6190's Interest Coverage is ranked worse than 69.5% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs TSE:6190: 17.25
PhoenixBio Co (TSE:6190) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
PhoenixBio Co Interest Coverage Related Terms
PhoenixBio Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for PhoenixBio Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TSE:6190 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, PhoenixBio Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhoenixBio Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PhoenixBio Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where PhoenixBio Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhoenixBio Co (TSE:6190) has a Interest Coverage of 32.12 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on PhoenixBio Co and its competitors. This is 34% below median its historical median of 48.72. Over the past decade, PhoenixBio Co's Interest Coverage has ranged from 3.78 to 165.51. According to the industry distribution chart, PhoenixBio Co ranks #262 out of 377 companies in the Biotechnology industry, placing it in the top 69.5%.
Is PhoenixBio Co's Interest Coverage too high?
PhoenixBio Co's current Interest Coverage of 32.12 is 34% below median its 10-year median of 48.72. Over the past 10 years, this metric has ranged from a low of 3.78 to a high of 165.51. The Biotechnology industry median Interest Coverage is 106.07. PhoenixBio Co's value of 32.12 is 69.7% below this industry median. Based on the distribution chart, PhoenixBio Co ranks #262 out of 377 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PhoenixBio Co has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PhoenixBio Co ranks #262 out of 377 companies for Interest Coverage. This places PhoenixBio Co in the lower half of its industry. The industry median Interest Coverage is 106.07. PhoenixBio Co's value of 32.12 is 69.7% below this benchmark. Historically, PhoenixBio Co's own Interest Coverage has ranged from 3.78 to 165.51 over the past decade. While the company's 10-year median is 48.72 vs. the industry median of 106.07, PhoenixBio Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhoenixBio Co's current Interest Coverage of 32.12 is 69.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on PhoenixBio Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhoenixBio Co's current Interest Coverage is 32.12, which is 34% below median its own 10-year median of 48.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Fairly Valued. The stock's GF Value™ is 円359.65, compared to a current price of 円336.00 — trading 6.6% below its estimated fair value. The current Interest Coverage is 32.12, which is 34% below median its 10-year median of 48.72 and 69.7% below the Biotechnology industry median of 106.07. PhoenixBio Co's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current Interest Coverage is 32.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhoenixBio Co (TSE:6190) Overvalued in 2026?
Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued.
The current stock price of 円336.00 is trading 6.6% below its estimated GF Value™ of 円359.65.
GuruFocus considers PhoenixBio Co to be Fairly Valued.
Key valuation signals for TSE:6190:
Interest Coverage: 32.12 (34% below median its 10-year median of 48.72)
GF Value™: 円359.65 vs. price of 円336.00 (6.6% below fair value)
Industry Position: 69.7% below the Biotechnology median (#262 of 377)
No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
57GF Score
Get the complete analysis for TSE:6190
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6190 has been successfully added to your 
